MARKET WIRESeekingAlpha • 5h ago
Wall Street Week AheadWall Streetâs big week: midterm elections, October jobs report and key earnings from Apple, AMD and Uber.
Why MRNA Stock surged +4.01% Today — RQD Quant Desk Flash
$222.76 +4.01% NASDAQ • Public Delayed / 60s Snapshot
Moderna Inc. (MRNA) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
ROARABLE C • HOLD / WATCH
Cap $88.93B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERHOLD / WATCH • C
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D+ · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+1.8% Base Target
WHALE OPTIONS TUG-OF-WAR:61% Call Buyers ($9.7M)
39% PutsMax Pain: $218.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why MRNA Stock surged +4.01% Today — RQD Quant Desk Flash
Moderna Inc. (MRNA) surged +4.01% to $222.76 as options desks priced 61% call premium vs. 39% put protection around the $218 max-pain magnet. Solid 55% profit margin (-34% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 86% of its 52-week range ($22.28 – $254.48) with RSI-14 at 57.3 (BULLISH MOMENTUM).
- ▸Whale Options Positioning: $9.7M in bullish call flow vs. $6.3M in put flow (Put/Call 0.65x, implied earnings swing ±7.2%).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 55.3% gross margin and $0 annual free cash flow.
Live MRNA Headlines & Catalysts
CATALYSTSeekingAlpha • 23h ago
The 1-Minute Market Report October 31, 2026The S&P 500 declined 0.6% last week, with AI and mega-cap growth stocks under heavy selling pressure. Discover more in this market report.
MARKET WIRESeekingAlpha • 1d ago
Apple Leads Packed Earnings Calendar As Investors Eye Tech, Pharma ResultsPreview next weekâs market movers: jobs data, PMI reports, major earnings from Apple and AMD, and IPO buzz. Read here for more details.
MARKET WIREYahoo • 1d ago
How Investors Are Reacting To Moderna Stock Phase 3 Melanoma Vaccine DataMerck and Moderna reported Phase 3 data from the INTerpath-001 trial in resected high-risk melanoma, where personalized mRNA therapy intismeran autogene plus KEYTRUDA reduced the risk of recurrence or death by 42% and di
MARKET WIREYahoo • 1d ago
This week in charts: ESMO’s winners and losersThe latest installment in BioPharma Dive’s visualization-focused series looks at Wall Street’s response to a trio of closely watched presentations at a top meeting for cancer drugs.
MARKET WIREYahoo • 1d ago
Prediction markets herald insider trading risks for private biotechsLegal experts say that pharma outcome bets on platforms like Kalshi and Polymarket pose new insider trading risks.
CATALYSTBenzinga • 1d ago
Merck One of Top Large-Cap Biopharma Picks-AnalystMerck beats Q3 estimates on oncology strength and raised guidance, while Guggenheim eyes pipeline progress ahead of Keytruda patent loss.
CATALYSTYahoo • 1d ago
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to DeclineModerna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CATALYSTYahoo • 1d ago
Merck & Co., Inc. Q3 Earnings Call HighlightsMerck & Co., Inc. (NYSE:MRK) reported third-quarter 2026 revenue of $18.1 billion, up 5% from a year earlier, as growth in oncology, vaccines, cardiometabolic products and animal health helped offset product-specific and
MARKET WIREYahoo • 2d ago
These 2 Stocks Have Skyrocketed in 2026. Here’s Why I’d Stay AwayThese biotechs’ valuations are through the roof.
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Trading Systems Desk
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live MRNA Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
MRNA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +382.63%▲ ASCENDING CHANNEL
2026-10-30O $220.5H $227.8L $217.2C $221.7VOL 9.00M
RES: $266.9SUP: $65.80SMA50: $182.5SMA200: $86.58
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
MRNA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
24.7%/yr Implied 5Y Growth
vs. -39.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on MRNA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for MRNA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MRNA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
MRNA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is MRNA stock moving today?
Why MRNA Stock surged +4.01% Today — RQD Quant Desk Flash. Solid 55% profit margin (-34% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.